The Journal of urology (J Urol)

Publisher: American Urological Association, Elsevier

Journal description

The most widely read publication in the field, The Journal of Urology® brings solid coverage of all the clinically relevant information needed to stay at the forefront of this dynamic field. The Journal presents investigative studies on critical areas of research and practice; survey articles providing short condensations of the best and most important urology literature worldwide; and practice-oriented reports on interesting clinical observations.

Current impact factor: 4.47

Impact Factor Rankings

2016 Impact Factor Available summer 2017
2014 / 2015 Impact Factor 4.471
2013 Impact Factor 3.753
2012 Impact Factor 3.696
2011 Impact Factor 3.746
2010 Impact Factor 3.862
2009 Impact Factor 4.016
2008 Impact Factor 3.952
2007 Impact Factor 4.053
2006 Impact Factor 3.956
2005 Impact Factor 3.592
2004 Impact Factor 3.713
2003 Impact Factor 3.297
2002 Impact Factor 3.03
2001 Impact Factor 3.19
2000 Impact Factor 2.896
1999 Impact Factor 2.486
1998 Impact Factor 2.685
1997 Impact Factor 2.719
1996 Impact Factor 2.668
1995 Impact Factor 2.792
1994 Impact Factor 2.539
1993 Impact Factor 2.231
1992 Impact Factor 1.91

Impact factor over time

Impact factor

Additional details

5-year impact 4.10
Cited half-life 9.60
Immediacy index 1.13
Eigenfactor 0.07
Article influence 1.27
Website Journal of Urology, The website
Other titles Journal of urology (Online), The journal of urology
ISSN 1527-3792
OCLC 42747133
Material type Document, Periodical, Internet resource
Document type Internet Resource, Computer File, Journal / Magazine / Newspaper

Publisher details


  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author can archive a post-print version
  • Conditions
    • Authors pre-print on any website, including arXiv and RePEC
    • Author's post-print on author's personal website immediately
    • Author's post-print on open access repository after an embargo period of between 12 months and 48 months
    • Permitted deposit due to Funding Body, Institutional and Governmental policy or mandate, may be required to comply with embargo periods of 12 months to 48 months
    • Author's post-print may be used to update arXiv and RepEC
    • Publisher's version/PDF cannot be used
    • Must link to publisher version with DOI
    • Author's post-print must be released with a Creative Commons Attribution Non-Commercial No Derivatives License
    • Publisher last reviewed on 03/06/2015
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Detection of DNA hypermethylation has emerged as novel molecular biomarker for prostate cancer (Pca) diagnosis and evaluation of prognosis. We intend to define whether a hypermethylation profile of patients with PCa under androgen deprivation (AD) predicts development of castrate-resistant prostate cancer. Material and methods: Genome-wide methylation analysis was performed using the GoldenGate Methylation Cancer Panel-I (Illumina,Inc.) on 10 normal prostates and 45 tumor samples from patients placed on AD and followed until development of castrate-resistant disease defined following EAU Guidelines criteria. Double pathologist review evaluated Gleason score, ki-67index and neuroendocrine differentiation. Hierarchical clustering analysis was performed and relationships with outcome were investigated using Cox regression and log-rank analysis. Results: We found 61 genes significantly hypermethylated in >20% of the tumors analyzed. Three clusters of patients were characterized by their DNA methylation profile, one at risk to develop earlier castrate-resistant disease (log-rank,p=0.019) and specific mortality (log-rank,p=0.002). Hypermethylation of ETV1 (HR3.75) and ZNF215 (HR2.89) predicted disease progression despite AD and hypermethylation of IRAK3 (HR13.72), ZNF215 (HR4.81) and SEPT9 (HR7.64) were independent markers of prognosis. PSA>25ng/ml, Gleason pattern 5, Ki-67index>12% and metastasis at diagnosis were also predictors of a negative response to AD. Limitations included retrospective design and limited series number. Conclusion: Epigenetic silencing of the aforementioned genes could be novel molecular markers for prognosis of advanced PCa and predict development of castrate-resistance during hormone deprivation and, consequently, disease-specific mortality. Gene hypermethylation is associated with disease progression in patients receiving hormone therapy and could be used as marker of treatment response.
    No preview · Article · Mar 2016 · The Journal of urology

  • No preview · Article · Mar 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Conditional estimates provide a dynamic prediction of outcomes, but there are no data for non-muscle invasive bladder cancer (NMIBC). The purpose of this study was to assess the changes in conditional recurrence and progression rates after transurethral resection of the bladder (TURB) and to explore the prognostic impact of established factors and risk groups over time. Methods: We retrospectively analyzed data from 1292 consecutive patients with a newly diagnosed Ta/T1 BC who underwent a TURB. The endpoints of this study were time to first recurrence and time to progression. Results: The 2-year recurrence rate at baseline was 36% and improved as a function of time that the patient had been free of disease recurrence. After 6-, 12-, 24-, 36-, and 48-months, the 2-year conditional recurrence rate improved to 31% (14% improvement compared with baseline), 22% (39%), 16% (56%), 13% (64%), and 11% (69%), respectively. Comparably, conditional progression rates improved with increasing follow-up, although relative differences were less distinct. The prognostic impact of established factors and the NMIBC risk group progressively decreased over time and finally disappeared. BCG, however, had a protective effect on progression even after 3 years. We also provide tables with dynamic prognostic information at all analyzed time points. Conclusions: In patients with primary Ta/T1 BC, recurrence and progression rates improve over time. The prognostic impact of established factors and risk groups decreases and finally disappears. The effect of BCG on progression is long-lasting. Conditional outcome estimates may improve patient counseling and individualize surveillance planning.
    No preview · Article · Feb 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: TWIST (Testicular Workup for Ischemia and Suspected Torsion) score uses urologic history and physical exam to assess risk of testis torsion. The parameters include testis swelling (2 points), hard testis (2), absent cremasteric reflex (1), nausea/vomiting (1), and high-riding testis (1). While TWIST has been validated when scored by urologists, its diagnostic accuracy amongst non-urologic providers is unknown. We assessed the utility of the TWIST score when collected by non-urologic non-physician providers, mirroring the ER evaluation of acute scrotal pain. Materials and methods: Pediatric patients with unilateral acute scrotum were prospectively enrolled in a NIH clinical trial. After undergoing basic history and physical exam training, EMTs calculated TWIST score and determined Tanner stage per a pictorial diagram. Clinical torsion was confirmed by surgical exploration. All data were captured into RedCap, and receiver operating characteristic (ROC) curves evaluated the diagnostic utility of TWIST. Results: Of 128 patients (mean age 11.3), 44 (mean age 13.0) had torsion. TWIST score cutoff values of 0 and 6 derived from ROC analysis identified 31 high, 57 intermediate, and 40 low risk patients (positive predictive value 93.5%; negative predictive value 100%). Conclusions: TWIST score assessed by non-urologists, such as EMTs, is accurate. Low risk patients do not require ultrasound to rule out torsion. High risk patients can proceed directly to surgery, avoiding the ultrasound in >50% of patients. In the future, EMTs and/or ER triage personnel could calculate TWIST score to guide radiologic workup and immediate surgical intervention at initial assessment long before urologic consultation.
    No preview · Article · Feb 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Larger size and clear cell histopathology are associated with worse outcomes for malignant renal tumors treated by radiofrequency ablation (RFA). We hypothesize that greater tumor enhancement may be a risk factor for RFA failure due to increased vascularity. Methods: A retrospective review of patients who underwent RFA for renal tumors with contrast-enhanced imaging available was performed. The change in Hounsfield units (HU) of the tumor from the non-contrast phase to the contrast-enhanced arterial phase was calculated. RFA failure rates for biopsy confirmed malignant tumors were compared using the chi-squared test. Multivariate logistic analysis was performed to assess predictive variables for RFA failure. Disease-free survival (DFS) was calculated using Kaplan-Meier analysis. Results: Ninety-nine patients with biopsy confirmed malignant renal tumors and contrast-enhanced imaging were identified. The incomplete ablation rate was significantly less for tumors that enhanced <60 HU vs. ≥60 HU (0.0% vs. 14.6%, p=0.005). On multivariate logistic regression analysis, tumor enhancement ≥60 HU (OR 1.14, p=0.008) remained a significant predictor for incomplete initial ablation. Five year DFS for size <3cm was 100% vs. 69.2% for size ≥3cm, p<0.01, while 5 year DFS for HU change <60 was 100% compared to 92.4% for HU change ≥60, p=0.24. Conclusion: Biopsy confirmed malignant renal tumors, which exhibit a change in enhancement of ≥60 HU, experience a higher rate of incomplete initial tumor ablation than tumors <60 HU. Size ≥ 3cm portends worse 5 year DFS after RFA. Degree of enhancement should be considered when counseling patients prior to RFA.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To evaluate urgency urinary incontinence outcomes for patients who underwent revision of a presumed obstructing synthetic mid-urethral sling and examine risk factors for persistent or de-novo symptoms after surgery. Materials and methods: From 2/1/2005 to 6/1/2013, 107 women underwent sling revision for new or worsening lower urinary tract symptoms after synthetic mid-urethral sling surgery. Patients were grouped based on urgency urinary incontinence symptoms and characteristics associated with persistent or de-novo symptoms after revision were examined using logistic regression models. Results: Median follow-up was 29 months (IQR13-53) and time to revision was 21 months (IQR5-48). Patients presenting for sling revision with urgency incontinence (n=68) were more likely to experience >6 months delay to revision vs. those presenting with obstructive voiding symptoms (n=39) (OR=3.25, 95%CI:1.33-7.92, p<0.01). After revision, urgency incontinence persisted in 76.5% (52/68) and was associated with pre-revision need for anticholinergic medication (OR=5.58, 95%CI:1.44-21.39, p=0.01) and smoking (OR=5.21, 95%CI:1.21-22.49, p=0.03). De-novo urgency incontinence developed in 43.6% (17/39) and was associated with de-novo stress incontinence (OR=15.9, 95%CI:3.2-78.3, p < 0.01). Women with post-revision urgency incontinence (de-novo or persistent) had higher UDI6 scores as opposed to patients with no or resolution of urgency incontinence respectively. Conclusions: Patients presenting with new or worsening urgency urinary incontinence after sling placement were more likely to undergo delayed revision compared to those presenting with obstructive voiding symptoms. There is a high rate of bothersome persistent and de-novo urgency incontinence after sling revision. Patient expectations should be managed accordingly prior to sling revision.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To propose a mathematical formula to calculate contact surface area between a tumor and renal parenchyma. We examined the applicability of using contact surface area to predict renal function after partial nephrectomy. Materials and methods: We performed this retrospective study in patients undergoing partial nephrectomy between January 2012 and December 2014. Based on abdominopelvic computerized tomography or magnetic resonance imaging, we calculated the contact surface area using the formula (2*π *Radius*Depth) developed by integral calculus. We then evaluated the correlation between contact surface area and perioperative parameters, and compared contact surface area and RENAL score in predicting a reduction in renal function. Results: Thirty-five, 26, and 45 patients received partial nephrectomy with open, laparoscopic, and robotic approaches, respectively. The mean±SD contact surface area was 30.7±26.1 cm(2), and the median (interquartile range) RENAL score was 7 (2.25). Spearman correlation analysis showed that contact surface area was significantly associated with estimated blood loss (p=0.04), operative time (p=0.04), and percent change of estimated glomerular filtration rate (p<0.001). In multivariate analysis contact surface area and RENAL score independently affected percent change of estimated glomerular filtration rate (p<0.001 and p=0.03, respectively). In ROC curve analysis, contact surface area was a better independent predictor of a more than 10% change in estimated glomerular filtration rate compared to RENAL score (AUC: 0.86 vs. 0.69). Conclusions: Using this simple mathematical method, contact surface area was associated with surgical outcomes. Compared with RENAL score, contact surface area was a better predictor of functional change after partial nephrectomy.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To guide the surgeon during laparoscopic or robot-assisted radical prostatectomy, an innovative laparoscopic/ultrasound fusion platform was developed, using a motorized 3D-transurethral ultrasound (TUUS) probe. The first preclinical evaluation of 3D-prostate visualization using TUUS and preliminary results of this new augmented reality are here presented. Method: The transurethral probe and laparoscopic/ultrasound registration were tested on realistic prostate phantoms made of standard polyvinyl chloride (PVC). Quality of TUUS images and detection of passive markers placed on the prostate's surface were evaluated on 2D-dynamic view and 3D-reconstruction. Secondly, an evaluation of the feasibility, precision and reproducibility of laparoscopic/TUUS registration was conducted using 4, 5, 6 and 7 markers to assess the optimal amount necessary. A Root Mean Square (RMS) error was obtained for each registration. Median RMS error with interquartile ranges (IQR) were calculated according to the number of markers RESULTS: TUUS was easy to manipulate and prostatic capsule well visualized in both 2D and 3D. Passive markers could precisely be localized in the volume. Laparoscopic/TUUS registration procedures were performed on 74 phantoms of various sizes and shape. All were successful, median RMS error was 1.1 mm (IQR: 0.8-1.4) and significantly associated to the number of landmarks (p=0.001), with the highest accuracy using 6 markers. Prostate volume, however, did not have an effect on the registration's precision. Conclusion: TUUS provided high-quality prostate reconstructions and easy markers' detection. Laparoscopic/ultrasound registration was successful with an acceptable millimetric precision. Further investigations are necessary to achieve sub-millimetric accuracy and assess the feasibility in a human model.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: To examine whether and how Sac-1004, a vascular-leakage blocker, restores erectile function in an animal models of diabetic erectile dysfunction. Materials and methods: Eight-week-old C57BL/6J mice were used and diabetes was induced by intraperitoneal injection of streptozotocin. At 8 weeks after induction of diabetes, the animals were divided into 6 groups: controls; diabetic mice receiving repeated intracavernous injections of PBS (days -3 and 0; 20 μL); and diabetic mice receiving repeated intracavernous injections of Sac-1004 (days -3 and 0; 1 μg, 2 μg, 5 μg, and 10 μg in 20 μL of PBS, respectively). One week after injection, erectile function was measured by cavernous nerve stimulation. The penis was then harvested for histologic examinations and Western blot analysis. Results: Local delivery of Sac-1004 into the corpus cavernosum restored erectile function in diabetic mice. The highest erectile response was noted at a dose of 5 μg, for which the response was comparable to that in the control group. Sac-1004 significantly increased cavernous endothelial and smooth muscle contents and induced eNOS phosphorylation (Ser1177). Sac-1004 decreased extravasation of oxidized-LDL by restoring endothelial cell-cell junction proteins and pericyte content. Sac-1004 also promoted tube formation in primary cultured mouse cavernous endothelial cells in vitro. Sac-1004-mediated cavernous angiogenesis and erectile function recovery was abolished by inhibition of angiopoietin-1-Tie2 signaling with soluble Tie2 antibody. Conclusion: Sac-1004 with the effect of angiogenesis and anti-permeability re-establishes structural and functional cavernous sinusoids, which will be a highly promising for future treatment of erectile dysfunction from vascular causes.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Activation of Hedgehog (Hh) signaling has been implicated in early stages of bladder cancer development, while loss of Hh signaling has been described during progression to more invasive disease. Itraconazole, an antifungal, is the only azole known to be a potent Hh pathway antagonist. We evaluated whether itraconazole use is associated with bladder cancer risk or progression. Materials and methods: A case-control study nested within a United Kingdom database included 13,440 bladder cancer cases and 52,421 matched controls between 1995 -2013. Use of itraconazole and other azoles was measured in number of prescriptions. Conditional logistic regression estimated adjusted odds-ratios (AOR) and 95% confidence intervals (CI) for the association of bladder cancer with ever use and increasing number of prescriptions for itraconazole. Logistic regression was used to determine whether relative to other azoles, if itraconazole use among patients diagnosed with bladder cancer is associated with invasive bladder cancer requiring cystectomy. Results: Use of itraconazole was not associated with the risk of bladder cancer relative to never use (ever use: AOR 0.89, 95%CI 0.70-1.14; ≥4 prescriptions: AOR 0.87 [0.42-1.81]). However, among patients diagnosed with bladder cancer, there was a significant increased risk of bladder cancer requiring cystectomy with itraconazole use (ever use: AOR 2.05 [1.12-3.38]; ≥2 prescriptions: AOR 2.30 [1.12-4.72]). Conclusion: Inhibition of the Hh pathway with itraconazole was not associated with risk of bladder cancer overall, but was associated with higher risk of invasive bladder cancer requiring cystectomy. These data provide clinical evidence supporting the role of Hh signaling in regulating bladder cancer progression.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Studies investigating effects of stress urinary incontinence (SUI) on sexual function of couples are scarce. We prospectively evaluated sexual function of couples, relationship between sexual function and quality of life (QoL), and compared QoL of females with or without SUI. Materials and methods: Sexually active females with or without SUI aged at least 21 years old, and their partners were recruited. The couples completed the Golombok Rust Inventory of Sexual Satisfaction (GRISS) and a single-item question on overall sexual experience 'Over the past 4 weeks, how satisfied have you been with your overall sexual life?' to assess sexual function. Additionally, females completed the International Consultation on Incontinence Questionnaire-Lower Urinary Tract Symptoms quality of life (ICIQ-LUTSqol) to assess QoL. Results: For sexual function assessment, 66 of 134 SUI couples (49.3%) and 95 of 176 couples without SUI (54.0%) were recruited. Females with SUI had lower overall sexual function (p<0.001), lower frequency of sexual intercourse (p<0.001), less satisfaction (p<0.001) and higher avoidance behavior (p=0.026). Partners of SUI females had more problems with erectile dysfunction (p=0.027), less satisfaction (p=0.006) and lower frequency of sexual intercourse (p=0.001), but no difference in overall GRISS score (p=0.093). SUI couples had poorer overall sexual experience (p<0.05). Females with SUI (n=120/134, response rate 89.6%) had poorer QoL compared with those without SUI (n=145/176, response rate 82.4%) (p<0.001). Sexual function and QoL were not significantly correlated (r=0.001,p=0.997). Conclusions: Female SUI is negatively associated with not only their own QoL and sexual function, but also their partners' sexual function.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Solute carrier family 26 member 6 (SLC26A6) is a multifunctional anion transporter, and plays a critical physiological role in the transport of oxalate anions. Recognizing genetic variant of SLC26A6 will advance our understanding of oxalate transport in the formation of calcium oxalate stone. Materials and methods: All non-synonymous SNPs (nsSNPs) reported in human SLC26A6 were investigated using four different in silico tools including SIFT, PROVEAN, PhD-SNP and MutPred. 426 subjects including 225 kidney stone cases and 201 healthy controls were collected for genotyping the candidate disease-associated nsSNP using an allele-specific PCR. Furthermore, the structural consequences due to the mutation were assessed using homology modeling and molecular dynamics simulation methods RESULTS: A nsSNP (rs184187143) was identified more probable disease-associated variant in SLC26A6 gene by in silico screening. The C allele carrier had a 6.1-fold increased kidney stone risk compared with G allele carriers in the nsSNP (OR=6.1; 95%CI, 1.36-27.38; p=0.007). The mutation from arginine to glycine leads to loss of two hydrogen bonds and unstable structure in STAS domain of SLC26A6. Conclusions: Our results indicate that the variant (G539R) in the SLC26A6 gene is associated with kidney stone risk, and provide a clear clue for further achieving insight into oxalate transport in the kidney stone formation.
    No preview · Article · Jan 2016 · The Journal of urology

  • No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Vesicoureteral reflux is the most common urinary tract abnormality in children. Although voiding cystourethrography is the gold standard for diagnosing reflux, it is invasive. The aim of the present study was to evaluate color Doppler ultrasonographic measurements of the ureteral jet angle (UJA) as a non-invasive screening tool for detecting reflux. Materials and methods: We retrospectively evaluated 125 pediatric patients, 250 renal units, who presented with urinary tract infections or hydronephrosis. All patients underwent color Doppler ultrasonography and voiding cystourethrography. The UJA was measured as the angle between the direction of the ureteral jet and interureteral ridge. Results: Reflux was diagnosed in 80 patients, 117 renal units. The mean value of the UJA was significantly higher in refluxing units (67.9 ± 18.7°) than in non-refluxing units (47.8 ± 17.3°, p < 0.0001). The angle value in each reflux grade became significantly higher according to its grade (p < 0.0001). The overall ability of the UJA to detect grade III-V or grade IV, V reflux, as given by the area under the receiver-operating characteristic curve, was 0.81 or 0.88, respectively. A cut-off angle ≥ 55° detected grade III-V or grade IV, V reflux with a sensitivity of 85.5% or 94.7%, respectively. A cut-off angle ≥ 70° diagnosed grade IV, V reflux with a sensitivity of 81.6% and specificity of 82.7%. Conclusions: Color Doppler ultrasonographic measurements of the UJA represent a simple and non-invasive method that is applicable as a screening tool to detect high grade vesicoureteral reflux in children.
    No preview · Article · Jan 2016 · The Journal of urology
  • [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: Partial nephrectomy is the accepted standard of care for treatment of small renal mass. The primary goal while performing a partial nephrectomy is cancer control with secondary important goals of maximizing renal function preservation with minimal perioperative morbidity. Recent studies have highlighted the importance of renal parenchymal quality and quantity after surgery rather than duration of ischemia in determining the long-term renal function. Our objectives are to review the available data regarding perioperative renal function optimization with special interest on ischemia during partial nephrectomy highlighting the controversies and establishing future lines of investigation. Material and methods: A comprehensive literature review was performed between 1970 and 2014 via MEDLINE, PUBMED and COCHRANE. Review was consistent with the PRISMA (Preferred Reporting Items for Systemic Reviews and Meta-Analysis) criteria. We used MESH terms for search including "acute kidney injury/failure," "carcinoma, renal cell/ carcinoma of kidney/ neoplasm of kidney," "kidney failure, chronic/end-stage kidney disease," "ischemia-reperfusion," "warm ischemia/cold ischemia". Relevant reviews were also included. Abstracts from major urological/surgical conferences were reviewed. All studies included were performed in adults, were written in English and had an abstract available for review. Results: Our traditional knowledge of renal ischemia is derived from animal studies, kidney transplant and retrospective partial nephrectomy studies that indicate the risk of renal function impairment from every single minute of ischemia. Careful evaluation of historical studies highlight the flaws of the use of ischemia duration as a dichotomous marker (25 or 30 min) while predicting renal functional outcomes. Recent studies have demonstrated no effect of duration of ischemia on ultimate kidney function both in the short and long term. Quality and quantity of parenchyma preserved after surgery are the key predictors of ultimate renal function after PN. Traditionally PN has been performed with hilar occlusion to provide relatively bloodless surgical field allowing effective oncologic control during tumor excision with secure management of blood vessels, collecting system and renal reconstruction. Selective clamping and nonclamping techniques have been proposed to obviate the perceived harmful effects of ischemia. Albeit, they convert a complex surgery into a more challenging procedure; potentially limiting the widespread use of PN for management of renal cancers. Promising urine and blood-based biomarkers (NGAL, KIM-1) in the context of critical care settings and global stress have shown to predict acute kidney injury. Within the PN environment, the utility of those markers still needs to be further investigated. None of the studies have proven its usefulness in the setting of PN up to date. Conclusion: The use of a single cut off value for duration of ischemia time as a dichotomous value for renal functional outcomes in the setting of partial nephrectomy is flawed based on available evidence. Renal ischemia is a controversial topic with a shifted paradigm within the last decade. Current evidence has shown that patients with two kidneys undergoing NSS can tolerate ischemia times of more than 30 minutes without a clinically significant decline in renal function. Biomarkers predictive of renal tubular injury failed to predict acute kidney injury in the context of partial nephrectomy. Indications for partial nephrectomy could be significantly expanded, as the safety of limited renal ischemia is now better understood.
    No preview · Article · Jan 2016 · The Journal of urology

  • No preview · Article · Jan 2016 · The Journal of urology

  • No preview · Article · Jan 2016 · The Journal of urology

  • No preview · Article · Jan 2016 · The Journal of urology